全球首个抗HCV全口服新药索非布韦

The World's First Oral Anti-hepatitis C Virus Drug Sofosbuvir

丙型肝炎病毒感染极大地威胁着公众健康,目前的标准治疗方案是聚乙二醇修饰的干扰素-α(PegIFN)与广谱抗病毒药物利巴韦林(RBV)联合,然而这种疗法的持续病毒学应答相对较低,新的研究如直接作用的抗病毒药(DAAs)提供了一种新的治疗策略,以提高疗效和耐受性。索非布韦是首个全口服抗丙型肝炎病毒药物,通过抑制NS5B聚合酶来有效抑制HCV的复制,从而达到治疗效果。本文主要就其化学合成、作用机理、药代动力学特征及临床疗效和安全性做一综述。

Hepatitis C virus infection greatly threaten the public health. Recently, the standard of care （SoC） for HCV treatment combined pegylated interferon - ct （PeglFN） with the broad spectrum antiviral ribavirin （ RBV ）. However, sustained viral responses （SVR） for this therapy is relatively low . Direct acting antivirals （ DAAs ） have now begun to address the need for improved treatment outcome and tolerability. Sofosbuvir is a HCV NS5B polymerase inhibitor. In this paper,we reviewed the chemical synthesis,mechanism, pharmacokinetics and clinical efficacy and safety of Sofosbuvir.